Skip to content

Early vs. Late Time-Restricted Eating in Adolescents With Obesity (EL TREA)

Early vs. Late Time-Restricted Eating in Adolescents With Obesity (EL TREA)

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05740254
Enrollment
94
Registered
2023-02-22
Start date
2023-03-27
Completion date
2026-06-01
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Obesity, Time Restricted Eating, Time Restricted Feeding

Keywords

Obesity, Intermitted-fasting, Time Limited Eating

Brief summary

Determine the effectiveness of how limiting the time you eat within an early or late eating window and fasting for remainder of the day will impact weight loss and body mass index (BMI).

Detailed description

In adults, there is growing evidence that early TRE is more effective in improving metabolic outcomes than other forms of TRE, however it is unclear whether adolescents will be able to adhere to such recommendations. Hence, in the present study we propose a 24-week, 2-arm, parallel randomized pilot trial in 100 adolescents (age 13-18 years, all gender expressions, anticipate 65% Latino) with obesity, to test the preliminary efficacy of early vs. late TRE on glycemic profiles, weight loss, and body composition. We hypothesize that, among adolescents who can adhere to the meal timing recommendations, early TRE will result in greater improvement in metabolic endpoints than late TRE. We will test the hypothesis with 3 specific aims: Aim 1: Test the effect of early vs. late TRE on glycemic profiles and β-cell function. Aim 2: Test the effect of early vs. late TRE on obesity and body composition, and cardiometabolic risk factors. Aim 3: Test the effect of early vs. late TRE on exploratory outcomes including sleep, physical activity, and dietary intake to explore how meal timing may influence occurrence, timing, and distribution of sleep and movement as well as dietary intake and caloric distribution. This study is the first study evaluating the effectiveness of early vs. late TRE in adolescents with obesity at risk for diabetes.

Interventions

Early Time Restricted Eating 7 AM to 3 PM

Late Time Restricted Eating 12 PM to 8 PM

Sponsors

Children's Hospital Los Angeles
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
12 Years to 21 Years
Healthy volunteers
No

Inclusion criteria

* 12-21 years with obesity (BMI\>95th percentile) * participant must be willing and able to adhere to the assessments, visit schedules, and eating/fasting periods * baseline eating window greater than 12 hours.

Exclusion criteria

* diagnosis of Prader-Willi Syndrome, brain tumor, or diabetes serious intellectual disability * previous diagnosis or subthreshold symptoms of an eating disorder (anorexia nervosa, bulimia nervosa, binge-eating disorder) * parent/guardian-reported physical, mental of other inability to participate in the assessments * previous bariatric surgery * current participation in other interventional weight loss studies.

Design outcomes

Primary

MeasureTime frameDescription
Mean change in weight in excess of the 95th percentile at week 24 compared to baselineweek 24Change in weight in excess of the 95th percentile

Secondary

MeasureTime frameDescription
Mean change in systolic and diastolic blood pressure at week 24 compared to baselineweek 24Measured systolic and diastolic blood pressure at baseline and week 24
Mean change in total body fat mass as measured on DEXA scan at week 24 compared to baselineweek 24Change in total body fat mass measured on DEXA scan
Mean change in percent time in range as captured on contiguous glucose monitor at week 24 compared to baselineweek 24%TIR captured on CGM
Mean change in hemoglobin A1c at week 24 compared to baselineweek 24HgA1c measured at baseline and week 24
Mean change in ALT at week 24 compared to baselineweek 24ALT measured at baseline and week 24

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORAlaina Vidmar, MD

Children's Hospital Los Angeles

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 1, 2026